AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7816407 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 71
Study 7816407 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 71
Study 7816407 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 71
Study 2836259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (2 X 2500 anti-Xa units on Day 1 and 1 X 5000 anti-Xa units from Days 2 to 8)
Number of subjects: 193
Study 2836259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin
Number of subjects: 193
Study 2836259 — intervention group
Group type: COMPARATOR
Intervention: heparin-dihydergot (HDHE) (2 X 5000 IU heparin with 0.5 mg DHE from Days 1 to 8)
Number of subjects: 193
Study 2836259 — intervention group
Group type: COMPARATOR
Intervention: heparin-dihydergot (HDHE)
Number of subjects: 193
Study 29129758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 29129758 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 26654869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention booklet group
Number of subjects: 136
Study 26654869 — intervention group
Group type: COMPARATOR
Intervention: General information booklet control group
Number of subjects: 136
Study 26654869 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 136
Study 24935282 — intervention group
Group type: EXPERIMENTAL
Intervention: FAc 0.2 μg/day
Number of subjects: 953
Study 24935282 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 953
Study 22875911 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative RT-PCR monitoring of minimal residual disease (MRD)
Number of subjects: 278
Study 20362397 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (benzodiazepine) in addition to mechanical physiotherapy and analgesics for 7 days
Number of subjects: 60
Study 20362397 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to mechanical physiotherapy and analgesics for 7 days
Number of subjects: 60
Study 20362397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20362397 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 60
Study 18456901 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-assisted self-administered parent training (SDPT+T)
Number of subjects: 69
Study 18456901 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WL)
Number of subjects: 69
Study 15917061 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of self-paced, non-supervised brisk walking, 5 days per week for 12 weeks (n = 21)
Number of subjects: 31
Study 15917061 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining habitual lifestyle (n = 10)
Number of subjects: 31
Study 15917061 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 31
Study 14601352 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XL (75 mg, with potential dose doubling after 2 weeks)
Number of subjects: 244
Study 14601352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 10424326 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue contact lenses soaked in 0.3% eye drop solutions
Number of subjects: 265
Study 10424326 — intervention group
Group type: COMPARATOR
Intervention: Eye drops (0.3% gentamicin, kanamycin, tobramycin, ciprofloxacin, or ofloxacin)
Number of subjects: 265
Study 8739655 — intervention group
Group type: EXPERIMENTAL
Intervention: Aredia (pamidronate) 90 mg i.v. every 4 weeks
Number of subjects: 377
Study 8739655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 1736944 — intervention group
Group type: EXPERIMENTAL
Intervention: NdYAG laser treatment
Number of subjects: 30
Study 1736944 — intervention group
Group type: COMPARATOR
Intervention: Control (unlased) teeth
Number of subjects: 30
Study 6496560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide tablets
Number of subjects: 0
Study 6496560 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxzide tablets
Number of subjects: 0
Study 6496560 — intervention group
Group type: COMPARATOR
Intervention: Dyazide capsules
Number of subjects: 0
Study 31489809 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyester pillow
Number of subjects: 92
Study 31489809 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex pillow
Number of subjects: 92
Study 31489809 — intervention group
Group type: COMPARATOR
Intervention: Usual pillow
Number of subjects: 92
Study 27452158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-physician collaborative care model
Number of subjects: 80
Study 27452158 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 27027547 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 258
Study 27027547 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin
Number of subjects: 258
Study 25200513 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born to the most educated mothers
Number of subjects: 12463
Study 25200513 — intervention group
Group type: EXPERIMENTAL
Intervention: Children of the most educated mothers
Number of subjects: 12463
Study 25200513 — intervention group
Group type: EXPERIMENTAL
Intervention: Children born to the most educated fathers or with a parent in a non-manual occupation
Number of subjects: 12463
Study 22438600 — intervention group
Group type: EXPERIMENTAL
Intervention: Mock-patient counseling activities
Number of subjects: 0
Study 22438600 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer role-play
Number of subjects: 0
Study 22438600 — intervention group
Group type: COMPARATOR
Intervention: Written dialogue
Number of subjects: 0
Study 20642247 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone extended release (ER)
Number of subjects: 80
Study 16996808 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 65
Study 16996808 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored behavioral self-management intervention via telephone by a nurse
Number of subjects: 65
Study 16996808 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of home blood pressure monitoring and tailored behavioral intervention
Number of subjects: 65
Study 16996808 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study 15623574 — intervention group
Group type: EXPERIMENTAL
Intervention: High mannan binding lectin (MBL) levels (>1,000 microg/L) in the cross-sectional group (n = 987)
Number of subjects: 1309
Study 15623574 — intervention group
Group type: EXPERIMENTAL
Intervention: High MBL at recruitment in the nested case-control group (n = 1,309)
Number of subjects: 1309
Study 15623574 — intervention group
Group type: EXPERIMENTAL
Intervention: High MBL in diabetic individuals
Number of subjects: 1309
Study 15623574 — intervention group
Group type: EXPERIMENTAL
Intervention: High MBL in hypercholesterolemic individuals
Number of subjects: 1309
Study 15623574 — intervention group
Group type: EXPERIMENTAL
Intervention: High MBL in individuals with raised erythrocyte sedimentation rate
Number of subjects: 1309
Study 15623574 — intervention group
Group type: EXPERIMENTAL
Intervention: High MBL in diabetic patients
Number of subjects: 1309
Study 12006323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 272
Study 12006323 — intervention group
Group type: COMPARATOR
Intervention: Parenteral gold
Number of subjects: 272
Study 9710004 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with degenerative dementia and RBD
Number of subjects: 37
Study 9710004 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Number of subjects: 37
Study 9710004 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical diagnosis of dementia with Lewy bodies (DLB)
Number of subjects: 37
Study 9710004 — intervention group
Group type: EXPERIMENTAL
Intervention: Autopsy findings
Number of subjects: 37
Study 7794044 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (THA) 20 mg in 1 ml
Number of subjects: 84
Study 7794044 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline, 1 ml)
Number of subjects: 84
Study 2214880 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month interferon regimen
Number of subjects: 20
Study 2214880 — intervention group
Group type: COMPARATOR
Intervention: 3-week interferon trial
Number of subjects: 20
Study 374428 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene
Number of subjects: 32
Study 374428 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 32
Study 374428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 374428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen and propoxyphene
Number of subjects: 32
Study 30557562 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil (40 mg for patients weighing <80 kg and 80 mg for patients weighing ≥80 kg)
Number of subjects: 1109
Study 30557562 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir phosphate
Number of subjects: 1109
Study 30557562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1109
Study 28592311 — intervention group
Group type: EXPERIMENTAL
Intervention: Green cardamom (500 mg capsules, three times/day for 3 months)
Number of subjects: 80
Study 28592311 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg capsules, three times/day for 3 months)
Number of subjects: 80
Study 24502675 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia implants (Ziterion vario Z(®))
Number of subjects: 22
Study 24502675 — intervention group
Group type: COMPARATOR
Intervention: Titanium implants (Ziterion vario T(®))
Number of subjects: 22
Study 23614370 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking-skill program emphasizing weight-bearing exercises
Number of subjects: 57
Study 23614370 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 57
Study 21783385 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty (HA)
Number of subjects: 55
Study 21783385 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 55
Study 19264155 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate 1 mg once a day for 12 months
Number of subjects: 270
Study 19264155 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 5 mg once a day for 12 months
Number of subjects: 270
Study 16317313 — intervention group
Group type: EXPERIMENTAL
Intervention: ziprasidone 80‐160 mg/day
Number of subjects: 306
Study 16317313 — intervention group
Group type: COMPARATOR
Intervention: chlorpromazine 200‐1200 mg/day
Number of subjects: 306
Study 15316206 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT)
Number of subjects: 28
Study 15316206 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 10898829 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene plus mid-potency corticosteroid
Number of subjects: 0
Study 10898829 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene plus superpotent corticosteroid
Number of subjects: 0
Study 10898829 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene
Number of subjects: 0
Study 9304445 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 52
Study 8329360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-enriched products (600 g/d)
Number of subjects: 24
Study 8329360 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg-enriched products (with added Mg)
Number of subjects: 24
Study 8329360 — intervention group
Group type: COMPARATOR
Intervention: Lactose intake (hydrolysis of lactose)
Number of subjects: 24
Study 3525068 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment with AVCF (Adriamycin, vincristine, cyclophosphamide, and 5-fluorouracil)
Number of subjects: 0
Study 3525068 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Number of subjects: 0
Study 28971224 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT) sling
Number of subjects: 92
Study 28971224 — intervention group
Group type: COMPARATOR
Intervention: Retropubic (RP) sling
Number of subjects: 92
Study 25758628 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg carbetocin shot
Number of subjects: 132
Study 25758628 — intervention group
Group type: COMPARATOR
Intervention: 20 IU oxytocin infusion
Number of subjects: 132
Study 24248532 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide
Number of subjects: 0
Study 24248532 — intervention group
Group type: COMPARATOR
Intervention: Semustine
Number of subjects: 0
Study 24248532 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (with mutant TP53 knockdown)
Number of subjects: 0
Study 24248532 — intervention group
Group type: COMPARATOR
Intervention: Semustine (with mutant TP53 knockdown)
Number of subjects: 0
Study 24248532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant TP53 expression
Number of subjects: 0
Study 24248532 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT expression
Number of subjects: 0
Study 22616615 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole and fulvestrant in combination with gefitinib
Number of subjects: 9
Study 20797953 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin care products (specific products not detailed)
Number of subjects: 208
Study 20797953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 19023831 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain framed messages with open label sustained-release (SR) bupropion
Number of subjects: 249
Study 19023831 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss framed messages with open label sustained-release (SR) bupropion
Number of subjects: 249
Study 19023831 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol use
Number of subjects: 249
Study 19023831 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence from alcohol
Number of subjects: 249
Study 19023831 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous alcohol use
Number of subjects: 249
Study 19023831 — intervention group
Group type: COMPARATOR
Intervention: AUD history
Number of subjects: 249
Study 16841678 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SI) low dose (0.3 ml/kg)
Number of subjects: 97
Study 16841678 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SI) high dose (0.6 ml/kg)
Number of subjects: 97
Study 16841678 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 97
Study 12636878 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-per-cycle pegfilgrastim 6 mg
Number of subjects: 453
Study 12636878 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-per-cycle pegfilgrastim 100 microg/kg
Number of subjects: 453
Study 12636878 — intervention group
Group type: COMPARATOR
Intervention: Daily filgrastim 5 microg/kg
Number of subjects: 453
Study 12636878 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pegfilgrastim and daily filgrastim
Number of subjects: 453
Study 12636878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg
Number of subjects: 453
Study 10812192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m² iv day 1, Vinorelbine 25 mg/m² iv days 1-8-15-22, Amifostine 740 mg/m² iv day 1 every 4 weeks up to six cycles
Number of subjects: 40
Study 10812192 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus Vinorelbine
Number of subjects: 40
Study 8859136 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 100
Study 8859136 — intervention group
Group type: COMPARATOR
Intervention: No local anesthetic
Number of subjects: 100
Study 1644464 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed high frequency electromagnetic energy (PHFE)
Number of subjects: 0
Study 1644464 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physiotherapy
Number of subjects: 0
Study 1644464 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of starting treatment
Number of subjects: 0
Study 6509461 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5, 5, or 10 mg once daily)
Number of subjects: 219
Study 6509461 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (100 mg once daily)
Number of subjects: 219
Study 30525950 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis 420™ (B420), 1010 cfu/d in 12 g microcrystalline cellulose
Number of subjects: 134
Study 30525950 — intervention group
Group type: EXPERIMENTAL
Intervention: Litesse® Ultra™ polydextrose (LU), 12 g/day
Number of subjects: 134
Study 30525950 — intervention group
Group type: EXPERIMENTAL
Intervention: Litesse® Ultra™ polydextrose (LU) + B420, 1010 cfu/d of B420 in 12 g/d LU
Number of subjects: 134
Study 30525950 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 12 g/d microcrystalline cellulose
Number of subjects: 134
Study 28834534 — intervention group
Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) therapy delivered in twice-weekly 30-minute sessions for 8 weeks
Number of subjects: 5
Study 28834534 — intervention group
Group type: EXPERIMENTAL
Intervention: Electropalatography (EPG) therapy
Number of subjects: 5
Study 26725132 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mm polyethylene (PE) inserts used during total knee arthroplasty
Number of subjects: 88
Study 26725132 — intervention group
Group type: COMPARATOR
Intervention: Trial insert sizes (1-mm smaller, same size, and 1-mm larger)
Number of subjects: 88
Study 25066659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit fiber bread
Number of subjects: 80
Study 25066659 — intervention group
Group type: EXPERIMENTAL
Intervention: FibreMax bread
Number of subjects: 80
Study 25066659 — intervention group
Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 80
Study 21959071 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol (20 mL of misoprostol solution 1 μg/mL orally every 1 hour for 4 doses then titrated to 40 μg every 1 hour)
Number of subjects: 64
Study 21959071 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral misoprostol (50 μg of misoprostol orally every 4 hours up to 12 hours)
Number of subjects: 64
Study 21959071 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (titrated and conventional)
Number of subjects: 64
Study 19666152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-culture-derived influenza vaccine (CCIV)
Number of subjects: 1200
Study 19666152 — intervention group
Group type: COMPARATOR
Intervention: Egg-based trivalent inactivated influenza vaccine (TIV)
Number of subjects: 1200
Study 17158048 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient involvement in multidisciplinary meeting
Number of subjects: 30
Study 17158048 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient attendance at the breast multidisciplinary meeting
Number of subjects: 30
Study 15522554 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year tamoxifen administration
Number of subjects: 256
Study 15522554 — intervention group
Group type: COMPARATOR
Intervention: 2-year tamoxifen administration
Number of subjects: 256
Study 11163295 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet (25/250 mg)
Number of subjects: 73
Study 9692700 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg b.d.; n = 10)
Number of subjects: 36
Study 9692700 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg b.d.; n = 10)
Number of subjects: 36
Study 9692700 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole (40 mg b.d.; n = 10)
Number of subjects: 36
Study 7826791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 0.75 mg kg‐1 and clonidine 75 micrograms intrathecally
Number of subjects: 0
Study 7826791 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 0
Study 7826791 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with morphine 0.5 mg
Number of subjects: 0
Study 7826791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine-clonidine
Number of subjects: 0
Study 3293526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg single dose
Number of subjects: 180
Study 3293526 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1,000 mg (500 mg doses given 12 h apart)
Number of subjects: 180
Study 31530046 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital physiotherapy treatment (early mobilization, ambulation, breathing exercises, thoracic range of motion exercises)
Number of subjects: 107
Study 31530046 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving in-hospital physiotherapy treatment)
Number of subjects: 107
Study 31530046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (study and control)
Number of subjects: 107
Study 29214920 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 9
Study 29214920 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo perceived as caffeine (PLA)
Number of subjects: 9
Study 29214920 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (baseline control)
Number of subjects: 9
Study 24877892 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally evocative PSAs about skin cancer
Number of subjects: 193
Study 24877892 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed emotional appeals in PSAs
Number of subjects: 193
Study 24877892 — intervention group
Group type: EXPERIMENTAL
Intervention: Audience reactions of fear to PSAs
Number of subjects: 193
Study 23727830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-test measurement of sequential effect before manipulation phase
Number of subjects: 0
Study 23727830 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-test measurement of sequential effect after manipulation phase with increased mechanical costs
Number of subjects: 0
Study 21284702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 5-400mg
Number of subjects: 12
Study 21284702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin ≥50mg
Number of subjects: 12
Study 21284702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21284702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 12